FCGR3A and systemic lupus erythematosus: Good clinical response to rituximab in both RA [11] and SLE [12] is associated with the higher affinity 158 V polymorphism in CD16a (FcγRIIIa) suggesting that FcγR-mediated mechanisms are important for B cell depletion.